Claude Nicaise
Independent Director
Board of Director
Minory Therapeutics
Japan
Biography
Dr Claude Nicaise is an established leader in clinical drug development and worldwide regulatory strategy with more than 30 years of experience in the pharmaceutical and biotechnology industry. After graduating in medicine from the Université Libre de Bruxelles he began working for Bristol-Myers Squibb becoming Director of Clinical Cancer Research; Executive Director of Infectious Diseases Clinical Research; Vice-President Worldwide Regulatory Science and Strategy Oncology, Infectious Disease and NeuroScience. During his tenure with BMS, Dr. Nicaise led the development and worldwide registration of compounds such as etoposide, ifosfamide, videx, reyatase, cefepime, tequin, abilify, Erbitux and dasatinib. Subsequently, he joined Alexion as Senior Vice President of Strategic development and Global Regulatory Affair in where he had a leadership role in completing the worldwide registration of Soliris and implementing its life-cycle management. Dr Nicaise has authored over a hundred papers in peer-reviewed journals or abstracts at international meetings, and is a member of a number of professional societies. Currently, Dr. Nicaise is board member at Sarepta Therapeutics.
Research Interest
Oncology, Clinical Research
